Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Open Access
- 31 October 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 120 (1), 88-96
- https://doi.org/10.1038/s41416-018-0298-0
Abstract
Pancreatic cancer (PC) hijacks innate cellular processes to promote cancer growth. We hypothesized that PC exploits PD-1/PD-L1 not only to avoid immune responses, but to directly enhance growth. We also hypothesized that immune checkpoint inhibitors (ICIs) have direct cytotoxicity in PC. We sought to elucidate therapeutic targeting of PD-1/PD-L1. PD-1 was assessed in PC cells, patient-derived organoids (PDOs), and clinical tissues. Then, PC cells were exposed to PD-L1 to evaluate proliferation. To test PD-1/PD-L1 signaling, cells were exposed to PD-L1 and MAPK was examined. Radio-immunoconjugates with anti-PD-1 drugs were developed to test uptake in patient-derived tumor xenografts (PDTXs). Next, PD-1 function was assessed by xenografting PD-1-knockdown cells. Finally, PC models were exposed to ICIs. PD-1 expression was demonstrated in PCs. PD-L1 exposure increased proliferation and activated MAPK. Imaging PDTXs revealed uptake of radio-immunoconjugates. PD-1 knockdown in vivo revealed 67% smaller volumes than controls. Finally, ICI treatment of both PDOs/PDTXs demonstrated cytotoxicity and anti-MEK1/2 combined with anti-PD-1 drugs produced highest cytotoxicity in PDOs/PDTXs. Our data reveal PCs innately express PD-1 and activate druggable oncogenic pathways supporting PDAC growth. Strategies directly targeting PC with novel ICI regimens may work with adaptive immune responses for optimal cytotoxicity.Keywords
This publication has 46 references indexed in Scilit:
- Integrated Genomic Characterization of Pancreatic Ductal AdenocarcinomaCancer Cell, 2017
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- CCR9‐mediated signaling through β‐catenin and identification of a novel CCR9 antagonistMolecular Oncology, 2015
- Organoid Models of Human and Mouse Ductal Pancreatic CancerCell, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer CellsPLOS ONE, 2012
- Chemokine Receptor CXCR4 Enhances Proliferation in Pancreatic Cancer Cells Through AKT and ERK Dependent PathwaysPancreas, 2010
- The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasiaGut, 2008